A Nigerian firm manufactures rapid diagnostic tests locally through the WHO tech transfer
In a landmark achievement for local
manufacturing, a Nigerian health technology company, Codix Bio, has been
selected to produce rapid diagnostic tests (RDTs) domestically. This initiative
is part of a technology transfer program led by the WHO and the Medicines
Patent Pool. The agreement allows the Nigerian firm to manufacture high-quality
tests for diseases like HIV, malaria, and syphilis using world-class technology
that was previously only available from foreign suppliers.
This is a significant step toward health
independence for Nigeria and the broader African continent. By producing these
essential diagnostic tools locally, the country can reduce its reliance on
expensive imports and ensure a steady supply during health emergencies. The
project aims to make life-saving diagnostics more affordable and accessible to
low-income populations. It serves as a model for how international partnerships
can empower local industries to solve regional health challenges from within.
Read the original article at: https://www.who.int/news/item/09-05-2025-who-and-medicines-patent-pool-announce-sublicensing-agreement-for-rapid-diagnostic-test-technology
Follow us on Instagram, Twitter, and Facebook to stay up to date with what's new in healthcare all around the world.
Comments
Post a Comment